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Globally, hundreds of millions of people are affected by musculoskeletal disorders (~10 million 
in the UK) [1]. Data presented from a pan-European study showed that one in three people are 
affected by musculoskeletal pain and disorders of the musculoskeletal system are the most common 
work-related health problem. From a survey of individuals who retired early on medical grounds or 
were on long-term sickness benefit, up to 60% cited musculoskeletal pain as the cause [2]. As well 
as these societal implications there is a significant economic cost associated with musculoskeletal 
health. The National Health Service (NHS) spends over £4 billion per year on the treatment of these 
conditions. It is estimated that approximately ten million working days are lost each year (second 
only to the stress, depression and anxiety category) bringing the cost to the wider UK economy to 
over £5.4 billion. In the US this figure has been reported as $849 billion (approximately 7.7% of the 
Gross Domestic Product (GDP)) [3].  It is widely accepted that these figures will continue to increase 
as a result of the ageing population and as such intensive clinical and scientific research is focused 
on developing and implementing strategies that promote the maintenance of tissue physiology and 
function – a theme often termed ‘healthy ageing’.
Hyaline cartilage tissue is present on the surface of long bones where it provides resistance to 
compressive forces, permits dissipation of biomechanical loads that would otherwise be placed on 
the subchondral bone and contributes to the low-friction movement of the diarthrodial joint. The 
functional properties of hyaline cartilage are directly related to the biochemistry and macromolecular 
architecture of the Extracellular Matrix (ECM) components, which are synthesised and organised 
by one cell type, the chondrocyte. Aggrecan is the predominant proteoglycan of hyaline cartilage 
and is largely responsible for creating the hydrostatic pressure that resists loading through the 
osmotic imbalance brought by the heavily sulphated, negatively charged Glycosaminoglycan 
(sGAG) sugars attached to the core protein. Between 50-80% of the dry weight of hyaline cartilage is 
collagen, principally the fibrillar collagen type II, which lends torsional stability and tensile strength 
to counter the swelling pressure inside the tissue and through intermolecular interactions influences 
the organisation of the ECM. Minor components such as small leucine-rich proteoglycans (SLRPs; 
e.g. decorin, biglycan), cell surface proteoglycans (e.g. perlecan, syndecans, glypicans) and Fibril-
Associated Collagens with Interrupted Triple Helices (FACIT) collagens (e.g. type, IX, XI, XIV, 
XVI) fine tune the tissue structure and regulate cell signalling events by controlling the release of 
bio-active growth factors and cytokines [4].
The homeostasis of hyaline cartilage is vital to the health and function of the tissue and disruption 
of the exquisite balance of ECM anabolism and catabolism results in the slow and progressive 
loss of macromolecular components and eventual degradation and failure of the tissue associated 
with chronic diseases such as OA. Because of it hypocellular and avascular properties, hyaline 
cartilage has a limited capacity for self-repair [4]. OA is now widely accepted as a whole organ 
disease affecting all of the tissues within the joint and whilst being an obvious target for regenerative 
medicine, given the societal burden of the ageing population, clinical interventions are restricted to 
weight reduction, physiotherapy and Non-Steroidal Anti-Inflammatory Drug (NSAIDs) regimens 
with surgical replacement of the joint in the advanced stages [5,6]. 
In the UK, surgical intervention may be performed in the treatment of symptomatic focal defects 
if conservative measures have failed. In some centres in Europe and the USA, prophylactic treatment 
in asymptomatic cases may be offered with their clinical aim being to resurface the articular defect 
delaying the onset of chronic degenerative disease. These patients, typically within the younger 
demographic of the population (< 40 years), can return to occupational and recreational activity 
with minimal societal and economic impact.
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The most common cartilage regeneration strategy is microfracture 
or marrow stimulation which involves arthroscopic abrasion of the 
calcified layer and puncturing the subchondral plate with a pick into 
the cancellous bone to encourage the infiltration of mesenchymal 
progenitor cells that differentiate into chondrogenic cells capable 
of ECM synthesis, deposition and organisation. This technique is 
limited in that the de novo cartilage has a fibro cartilage phenotype 
with higher ratios of collagen type I: collagen type II and versican: 
aggrecan than the biomechanically superior hyaline cartilage [7]. It 
is limited to the defect sizes of < 2cm2 and focal arthroplasties, either 
metal or BioPoly™, are available for medium-sized defects in older 
patients.
There is therefore a significant clinical need to develop cartilage 
tissue regeneration strategies that not only meet the growing demand 
for surgeries within the younger population demographic, but also 
to improve the quality of the cartilage that is formed and thus the 
likelihood for successful clinical outcome. The options available 
include implantation of whole tissue grafts or the use of chrondrogenic 
cellular therapies.
Osteochondral tissue grafts are used to repair large full thickness 
cartilage defects created by trauma or pathology. Pioneering research 
investigating the potential for storing allogeneic osteochondral 
grafts at low temperature with nutrient supplementation to prolong 
chondrocyte viability, metabolic activity and maintenance of tissue 
integrity has increased the amount of available donor tissue, enabling 
the devolution of the procedure away from specialised centres and 
into routine surgical practice as more patients can be treated [8]. It is 
likely that further knowledge of bio-processing parameters including 
media formulations, gaseous tension and pH will continue to prolong 
the maintenance of tissue quality during storage. This, together with 
an increased knowledge regarding the biological changes that occur 
within different clinical cohorts of donor tissue (e.g. the effect of age 
or underlying co-morbidity) will serve to stratify and broaden the 
spectrum of available tissue to meet increasing demand.  
The advent of multi-disciplinary tissue engineering strategies 
bringing together expertise in cell biology, natural and synthetic 
scaffold materials and bioengineering has expanded the potential 
for advanced regeneration approaches for the treatment of larger 
lesions. The first of these, Autologous Chondrocyte Implantation 
(ACI), has been used clinically for over twenty years and is carried 
out as a two-stage procedure in which a biopsy of cartilage tissue 
is harvested for the isolation and ex vivo expansion of chondrocyte 
populations that are transplanted back at the site of the cartilage 
lesion. ACI and third generation techniques are challenged by the 
ability to harvest sufficient tissue and the rapid loss of chondrocyte 
phenotype as they divide in culture. Currently these procedures are 
indicated for use in larger lesions up to 20cm2. Research has over the 
past decade sought to investigate the use of stem cell populations 
as an alternative or additional choice of cell source. Mesenchymal 
stem cells (MSCs) are adult stem cells that can be isolated from 
multiple tissues (e.g. Bone marrow, synovium, muscle, adipose), 
expanded though many population doublings and differentiated 
into cell lineages relevant to the treatment of orthopaedic clinical 
indications including chondrocytes [9]. Furthermore embryonic 
stem cells, derived from the inner cell mass of embryos can undergo 
in vitro directed differentiation toward a chondrogenic cell lineage 
which lacks expression of hypertrophic collagen type X, leading to 
the suggestion that these cells have a more developmentally-relevant 
hyaline cartilage phenotype in contrast to MSC-derived chondrocytes 
[10, 11]. An additional benefit to ESCs as an allogeneic cell source is 
the potential for scaled-up manufacture and production of multiple 
treatment units from a single batch and hence a prospective reduced 
cost of per patient over the long term. 
The number of ground-breaking scientific developments being 
made in the laboratory will open up a future of more personalised 
treatment options yielding more successful clinical outcomes. 
However, classification of these cell-based therapies as Advanced 
Therapy Medicinal Products (ATMPs) subjects them to what may 
be perceived as a complex regulatory framework with extensive and 
robust pre-clinical evaluations during the R&D stage and multicentre 
Randomized Clinical Trials (RCTs) to demonstrate safety and 
efficacy profiles for licensing by the European Medicines Agency 
(EMA). Presently ACI and third generation techniques are the only 
cell-based therapies licensed for surgical use by clinicians in the 
knee. An evidence-based UK consensus statement prepared by 104 
clinicians concluded that ACI was the preferred treatment option 
for cartilage defects over microfracture with particular consideration 
for larger-sized defects [12]. Despite this the decision for ACI to be 
widely offered through the UK’s largest healthcare provider, the NHS, 
is still being debated with questions over the evidence of efficacy and 
cost-reimbursement still being considered.
The creation of the UK Regenerative Medicine Platform (UKRMP) 
to develop technologies that meet the challenges associated with the 
application of regenerative medicine (e.g. Delivery of cells and drugs, 
manufacture, safety and immunological modulation) alongside the 
Cell Therapy Catapult aims to provide the necessary infrastructure 
for facilitating and streamlining efficient clinical translation, placing 
the UK at the forefront of delivering regenerative medicine into 
clinical practice. 
Nevertheless, the delivery of cell-based chondrogenic cell 
therapies into widespread clinical practice remains a long way off and 
a two-pronged strategy of research into the development of protocols 
that optimise the quality of osteochondral grafts together with robust 
RCTs for evaluating chondrogenic cell therapies will be required to 
meet the increasing demand brought by the ageing population. 
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